Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Natera, Inc., a leader in ... in Ultrasound in Obstetrics & Gynecology ... prenatal test (NIPT) can identify a complete molar ... A study based upon data collected in the ... about 1 in 1,000 pregnancies, although other studies ...
(Date:5/28/2015)... TX (PRWEB) May 28, 2015 ... association serving and representing the life sciences industry ... Board of Directors meeting at The Foundry in ... of the organization brought together a broad spectrum ... and underscored the organization's early successes in partnering ...
(Date:5/28/2015)... MARLBOROUGH, Mass. , May 28, 2015 ... company focused on discovering and developing innovative therapeutics, primarily ... the pricing of a public offering of 26 million ... per share for gross proceeds of approximately $10.4 million. ... stock, (ii) a 13-month overallotment purchase right to purchase ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
Breaking Biology Technology:First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2
... via Single ... Platform, MirixaPro(SM), RESTON, Va. and WASHINGTON, Oct. ... creator of,the Diabetes Ten City Challenge and a partner in the ... that will,deliver all of APhA Foundation,s HealthMapRx commercial programs via,Mirixa. MirixaPro(SM) ...
... Oct. 9 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ... technology, ePRO and other services to the pharmaceutical,biotechnology, ... will release its 2008 third quarter results for ... 30, 2008 after the market closes.,After the release, ...
... CEL-SCI Corporation,(NYSE: CVM ) announced today ... facility for its lead drug Multikine(R). This dedicated,facility, ... Multikine that,will be used for CEL-SCI,s pivotal Phase ... head and neck cancer patients, and,subsequently for sale ...
Cached Biology Technology:Mirixa Corporation and the APhA Foundation Form Partnership 2Mirixa Corporation and the APhA Foundation Form Partnership 3eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008 2CEL-SCI Takes Delivery of New Manufacturing Facility 2
(Date:5/28/2015)... Va. , May 28, 2015 ... release of a new report titled "Markets for ... (reversible polymers, inorganic capsule and vascular systems, biomaterials, ... will grow to around $2.7 billion by 2020. ... from n-tech,s extensive coverage of smart materials. Other recent ...
(Date:5/27/2015)... May 27, 2015   Codonics ... systems and image documentation solutions and ... technologically-advanced automation solutions, is pleased to announce ... Codonics® Safe Label System® (SLS), an award-winning ... with the Omnicell Anesthesia Workstation, helps prevent ...
(Date:5/26/2015)... , May 26, 2015 ... the addition of the "Saudi Arabia Biometric ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... is projected to grow at over ... growth is attributed to the surging demand for ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... (BRONX, NY) "It,s in their genes" is a common ... to reach age 100 and beyond. Up until now, ... advantage such as high levels of HDL ("good") cholesterol. But ... Ferkauf Graduate School of Psychology of Yeshiva University ...
... San Diego have discovered that a small dose of a ... and affects their ability to recruit their nestmates to otherwise ... in this week,s issue of the Journal of Experimental ... to bee-pollinated crops and shed light on one of the ...
... in German . , Tobacco: actually pretty bad food ... of wild tobacco ( Nicotiana attenuata ). When this plant grows ... by tobacco hornworm larvae ( Manduca sexta ). This specialist insect ... a defense against its enemies. When researchers from the Max Planck ...
Cached Biology News:'Personality genes' may help account for longevity 2Commonly used pesticide turns honey bees into 'picky eaters' 2Deterring signals: Tobacco plants advertise their defensive readiness to attacking leafhoppers 2Deterring signals: Tobacco plants advertise their defensive readiness to attacking leafhoppers 3Deterring signals: Tobacco plants advertise their defensive readiness to attacking leafhoppers 4
...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
... sequences: Two separate vials containing ... the same sequence used as antigens ... No. 160890) To ... guanylate cyclase polyclonal antiserum (Catalog No. ...
Biology Products: